12 . 05 . 2016

Xeltis bioabsorbable cardiovascular technology clinical data are late breaker at AATS

AATS annual meeting 2016 logo_small

Results from the first clinical trial conducted on Xeltis bioabsorbable cardiovascular device will be presented as late breaker to leading cardiothoracic surgeons at 96th annual meeting of American Association of Thoracic Surgery (AATS).

World-renowned cardiac surgeon and leading investigator of the trial, Professor Leo Bockeria, will present the results in Baltimore on May 17 at 2pm ET.

The clinical trial was the first-ever to explore Endogenous Tissue Restoration (ETR) in patients, potentially a new revolutionary approach in cardiovascular treatment.

View preliminary program

Go back